Gain Therapeutics is a biotech company that targets lysosomal enzymes to develop drugs for pediatric genetic and selected central nervous system disorders. It offers structurally targeted allosteric regulators identified through its platform, SEE-Tx. The company develops treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders.